Olaparix 150MG (Olaparib)

Basic Product Information of Olaparix 150MG (Olaparib)

How Olaparix 150MG (Olaparib) Works PARP Inhibition and Synthetic Lethality

Olaparib, the active ingredient in Olaparix 150MG, is a selective and potent inhibitor of Poly ADP-Ribose Polymerase enzymes PARP1 and PARP2. PARP enzymes are critical components of the base excision repair (BER) pathway the mechanism cancer cells rely upon to repair single-strand DNA breaks. In patients with germline or somatic BRCA1 or BRCA2 mutations, the homologous recombination (HR) DNA repair pathway is already defective, leaving tumour cells uniquely dependent on PARP-mediated repair for survival.

Olaparib blocks PARP1 and PARP2 activity and also traps PARP-DNA complexes at sites of single-strand DNA breaks, preventing repair and causing replication fork stalling. In BRCA-mutated cancer cells that cannot perform homologous recombination, this dual action produces irreparable double-strand DNA breaks, triggering apoptotic cancer cell death through the principle of synthetic lethality. Normal cells with intact BRCA function retain the ability to repair these breaks via homologous recombination, meaning Olaparib selectively destroys tumour cells while sparing healthy tissue. This targeted oncological mechanism underpins why Olaparix 150MG represents a precision medicine advance for BRCA-positive cancers. Mediaid Pharmacy’s oncology medicines catalogue covers a broad range of targeted therapies for multiple cancer types.

Unlike cytotoxic chemotherapy, which broadly damages all rapidly dividing cells, Olaparix exploits a specific molecular vulnerability in BRCA-deficient tumours. This selectivity translates into a clinically meaningful and well-characterised tolerability profile compared to conventional platinum-based chemotherapy regimens. In the SOLO-1 trial, Olaparib maintenance therapy demonstrated a progression-free survival (PFS) benefit of 36.0 months versus 13.8 months on placebo in newly diagnosed BRCA-mutated advanced ovarian cancer patients who achieved a complete or partial response to first-line platinum chemotherapy establishing Olaparib as the definitive standard-of-care PARP inhibitor in this setting.

Approved Indications for Olaparix 150MG (Olaparib)

Olaparix (Olaparib) 150mg is approved for the following clinical indications in adult patients with confirmed BRCA mutations:

Key Clinical Benefits of Olaparix (Olaparib) 150MG

How to Take Olaparix 150MG (Olaparib) Dosage Guidelines

Clinical Monitoring Requirements During Olaparix Treatment

Regular clinical monitoring is mandatory throughout Olaparix (Olaparib) treatment. Oncologists and haematologists must monitor patients for haematological toxicities, as Olaparib commonly causes anaemia, thrombocytopenia, neutropenia, and leukopenia requiring close blood count surveillance. Monitoring parameters include Complete Blood Count (CBC) before treatment initiation, monthly for the first 12 months of treatment, and periodically thereafter; renal function assessed via serum creatinine and estimated GFR at baseline and during dose adjustment; and clinical assessment for signs of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) patients who develop MDS or AML confirmed by specialist haematology evaluation must discontinue Olaparix permanently. Patients should also be monitored for signs and symptoms of Pneumonitis, a rare but potentially serious pulmonary adverse reaction requiring treatment interruption and investigation if suspected.

Drug Interactions and Important Safety Information for Olaparix

Concomitant use of Olaparix with strong or moderate CYP3A inhibitors including itraconazole, ketoconazole, clarithromycin, erythromycin, verapamil, and grapefruit or Seville orange juice must be avoided wherever possible, as CYP3A inhibition significantly increases Olaparib plasma concentrations and associated toxicity risk. If a moderate CYP3A inhibitor cannot be avoided, the Olaparib dose must be reduced to 100mg twice daily, with careful monitoring.

Strong or moderate CYP3A inducers such as rifampicin, phenytoin, carbamazepine, and St. John’s Wort must be strictly avoided during Olaparix therapy. These agents markedly decrease Olaparib plasma concentrations and are expected to substantially reduce efficacy. Patients should inform their oncologist of all medications, supplements, and herbal products before initiating Olaparix. Co-administration with other DNA-damaging agents or myelosuppressive medicines increases the risk of additive haematological toxicity and should only be considered under specialist supervision.

Side Effects and Precautions of Olaparix 150MG (Olaparib)

Who Should Use Olaparix 150MG (Olaparib)?

Olaparix is indicated for adult patients diagnosed with BRCA1 or BRCA2-mutated cancers specifically advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer; HER2-negative locally advanced or metastatic breast cancer; metastatic castration-resistant prostate cancer (mCRPC); and metastatic pancreatic adenocarcinoma as detailed in the approved indications above. All patients must undergo validated BRCA mutation testing using an approved companion diagnostic before initiating Olaparib, as treatment is indicated only for those with confirmed deleterious or suspected deleterious germline or somatic BRCA1/2 mutations. Olaparix is prescribed exclusively by oncologists and specialist physicians with expertise in managing hereditary cancers and targeted oncology therapies. A full pre-treatment medical assessment including complete blood count (CBC), renal function, hepatic function, and BRCA biomarker testing is mandatory before initiating therapy. For patients whose treatment plans extend across multiple oncology agents, Mediaid Pharmacy’s oncology specialty medicines portfolio provides a comprehensive range of targeted cancer therapies to support multidisciplinary oncology management.

Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh and the number one oncology and specialty medicine company in the country. Beacon was the first company in Bangladesh to export cancer drugs and currently exports to markets across Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards. Olaparix 150MG (Olaparib) is one of Beacon’s internationally recognised precision oncology products, offering a high-quality, bioequivalent, and affordable alternative to Lynparza by AstraZeneca and MSD at a fraction of the originator cost. Every batch exported by Beacon meets the quality benchmarks required for approval in regulated international markets.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Olaparix (Olaparib)

Mediaid Pharmacy is a trusted global supplier of specialty, autoimmune, and oncology medications. Olaparix (Olaparib) 150mg is available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Europe, and beyond. Our team provides full order support including pricing, availability confirmation, documentation, and delivery tracking. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for enquiries.

Why Choose Olaparix (Olaparib) from Mediaid Pharmacy?

Olaparix represents a clinically proven advance in precision oncology for patients with BRCA-mutated cancers. As the generic bioequivalent of Lynparza by AstraZeneca and MSD, Olaparix delivers the same active ingredient Olaparib with the same validated PARP1 and PARP2 inhibition mechanism and synthetic lethality in BRCA-deficient tumours, at a dramatically more affordable price point. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy with worldwide shipping, Olaparix gives patients and oncologists access to high-quality targeted cancer therapy without the financial barrier of brand-name pricing. For patients whose comprehensive treatment plans also require additional targeted therapies or supportive cancer medicines, Mediaid Pharmacy’s oncology medicines section provides a comprehensive range of specialty oncology products sourced from verified manufacturers. For any patient or oncologist seeking a proven, affordable, and globally accessible Olaparib treatment option, Olaparix from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Olaparix 150MG (Olaparib)